Catalent is a holding company. Through its subsidiaries, the company is a provider of delivery technologies and development solutions for drugs, biologics and consumer health products. The company operates in four segments: Softgel Technologies, which provides formulation, development and manufacturing services for soft capsules; Biologics and Specialty Drug Delivery, which provides drug substance development and manufacturing; Oral Drug Delivery, which provides various formulation development and manufacturing technologies; and Clinical Supply Services, which provides manufacturing, packaging, storage, distribution, project management, and inventory management for drugs and biologics in clinical trials.

Enterprise Products Partners is a provider of midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals and refined products. The company's midstream energy operations include: natural gas gathering, treating, processing, transportation and storage; NGL transportation, fractionation, storage, and export and import terminals; crude oil gathering, transportation, storage, and export and import terminals; petrochemical and refined products transportation, storage, export and import terminals, and related services; and a marine transportation business that operates primarily on the U.S. inland and Intracoastal Waterway systems.

HG Holdings has an interest in HC Government Realty Trust, Inc., which owns and operates a portfolio of single-tenant properties leased throughout the United States for occupancy by federal agencies including the Federal Bureau of Investigation, the Drug Enforcement Administration, the Social Security Administration and the Department of Transportation.

Intellicheck is a technology company engaged in developing, integrating and marketing threat identification and identity authentication solutions. The company's products include Retail ID?, a solution for preventing fraud in the retail industry; Age ID?, a smartphone or tablet-based solution for preventing sale of age-restricted products to minors; PORT ID?, which provides, ports and facilities with an integrated way to validate ID credentials of individuals requesting entry to secure areas; and Defense ID?, a mobile and fixed infrastructure solution for threat identification, identity authentication and access control to military bases and other government facilities.

Macerich is a self-administered and self-managed real estate investment trust. The company is involved in the acquisition, ownership, development, redevelopment, management and leasing of regional and community/power shopping centers. The company is the sole general partner of, and owns a majority of the ownership interests in, The Macerich Partnership, L.P. (the Operating Partnership). The Operating Partnership owns or has an ownership interest in regional shopping centers and community/power shopping centers. The company conducts all of its operations through the Operating Partnership and its management companies, including Macerich Property Management Company, LLC and Macerich Management Company.

MSG Network is a holding company. Through its subsidiaries, the company is engaged in sports production, and content development and distribution, owns and operates two regional sports and entertainment networks, MSG Network (MSGN) and MSG+. The company's networks are distributed throughout all of New York State and main portions of New Jersey and Connecticut, as well as parts of Pennsylvania. The company's networks are also carried nationally by certain distributors on sports tiers or in similar packages. MSGN and MSG+ aired live professional games this past year, along with a lineup of other sporting events, including college football and basketball, as well as original programming.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

Sutter Rock Capital is an externally managed, non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.